A Phase 4 interventional study of Pregabalin and Dexmedetomidine in Pregabalin, Delirium Treatment and Coronary Artery Bypass Grafting, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by Tanta University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing dexmedetomidine in Delirium — 14 open to participants now, 17 under way, 4 of them phase 3. Dexmedetomidine · Delirium.
Among the 78 studies testing dexmedetomidine in Delirium, this one is the 46th largest by planned enrollment, is one of 7 that started in 2022, is one of 35 in phase 4, reaches primary completion later than 5 of the 16 other live ones, and was the 65th registered.
935 studies on the registry are indexed under Delirium; 188 are open to participants now.
Browse Delirium studies →14 of the 78 studies testing dexmedetomidine in Delirium are open now, in 5 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 60+
Tanta University · Sites in Egypt
Ages 21+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Douglas Fraser · Sites in Canada
Ages 1 mo–17 yrs
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 60+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 12 · Phase 4 35
First in 2004; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 111 across 551 interventional studies indexed under Delirium.
Median enrollment 98 across the 78 interventional studies. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 78 have an industry lead sponsor. The 10 most frequent:
Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Tanta University has 5 studies filed under Delirium — fewer than ten, so there is no comparison to draw.
3 of the studies testing dexmedetomidine in Delirium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06192615Phase 3Massachusetts General HospitalMinimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II) | 2027-10-31 |
| NCT04669457University of Massachusetts, WorcesterPediatric Delirium | 2027-04-05 |
| NCT07781462Alexandria UniversityIntravenous Infusion of Low Dose Ketamine Versus Dexmedetomedine for Delirium Treatment in Acute Heart Failure | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies testing dexmedetomidine in Delirium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.
Delirium is an acute brain disorder that involves changes in consciousness, attention, cognition, and perception.The incidence of postoperative delirium (POD) is high among patients undergoing cardiac surgery, ranging from 20 to 50%, and the risk is even higher in the elderly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
Drug: Pregabalin
Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/h.
Drug: Dexmedetomidine
Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.
Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)
Percent of delirium treatment
Assessment of delirium will be performed preoperatively and postoperatively at 12-h intervals or as needed according to the patient's condition using the confusion assessment method (CAM)
Time frame: 24 hour postoperatively
Level of sedation
Sedation level will be assessed by using the Ramsey sedation scale.
Time frame: 24 hour postoperatively
Incidence of weaning from mechanical ventilation
percent of patients who weaned from mechanical ventilation
Time frame: 1 week postoperatively
Length of hospital stay
Time frame: 1 month postoperatively
Plan to share: Yes — The data will available upon reasonable request from the principal investigator
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for May 2026, 41 months after the start.
Of 40 non-industry phase 4 interventional studies under Delirium, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 62. This study's planned 41 months is close to that.
Counting every sponsor, half of 40 studies reached it within 44 months; a quarter within 25 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pregabalin · Dexmedetomidine